TrialStudy of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Trial details
- Registry ID
- NCT06173531
- Phase
- Phase 3
Drug research
Carbetocin
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as ACP-101
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06173531 | ACAD | Phase 3 | Active not recruiting | 2025-10Estimated |
| OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06420297 | ACAD | Phase 3 | Terminated | 2025-12-19Actual |
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Trial details
- Registry ID
- NCT06420297
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |